It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fetal growth restriction (FGR), followed by postnatal early catch-up growth, is associated with an increased risk of metabolic dysfunction, including type 2 diabetes in humans. This study aims to determine the effects of FGR and early catch-up growth after birth on the pathogenesis of type 2 diabetes, with particular attention to glucose tolerance, pancreatic islet morphology, and fibrosis, and to elucidate its mechanism using proteomics analysis. The FGR rat model was made by inducing mild intrauterine hypoperfusion using ameroid constrictors (ACs). On day 17 of pregnancy, ACs were affixed to the uterine and ovarian arteries bilaterally, causing a 20.9% reduction in birth weight compared to sham pups. On postnatal day 4 (P4), the pups were assigned to either the good nutrition (GN) groups with 5 pups per dam to ensure postnatal catch-up growth or poor nutrition groups with 15 pups per dam to maintain lower body weight. After weaning, all pups were fed regular chow food ad libitum (P21). Rats in both FGR groups developed glucose intolerance; however, male rats in the FGR good nutrition (FGR-GN) group also developed hypertriglyceridemia and dysmorphic pancreatic islets with fibrosis. A comprehensive and functional analysis of proteins expressed in the pancreas showed that FGR, followed by early catch-up growth, severely aggravated cell adhesion-related protein expression in male offspring. Thus, FGR and early catch-up growth caused pancreatic islet morphological abnormalities and fibrosis associated with the disturbance of cell adhesion-related protein expressions. These changes likely induce glucose intolerance and dyslipidemia in male rats.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Nagoya University Hospital, Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya, Japan (GRID:grid.437848.4) (ISNI:0000 0004 0569 8970); Nagoya University Graduate School of Medicine, Department of Pediatrics, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
2 Nagoya University Hospital, Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya, Japan (GRID:grid.437848.4) (ISNI:0000 0004 0569 8970); Sanyo-Onoda City University, Department of Toxicology and Health Science, Faculty of Pharmaceutical Sciences, Sanyoonoda, Japan (GRID:grid.469470.8) (ISNI:0000 0004 0617 5071)
3 Nagoya University Hospital, Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya, Japan (GRID:grid.437848.4) (ISNI:0000 0004 0569 8970)
4 Kyoto Women’s University, Department of Food and Nutrition, Kyoto, Japan (GRID:grid.411223.7) (ISNI:0000 0001 0666 1238)
5 Nagoya University Graduate School of Medicine, Department of Pediatrics, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)